Table 1. Overview of patients, specimens, and analytical methods.
| № | Sex | Age |
*Type of glioma
disease (autopsy) Ki-67 (%), CD117+ cells (%) |
Tumor location and
dimensions (MRI) |
Cause of death
(in control group) |
Methods |
|---|---|---|---|---|---|---|
| Glioblastomas | ||||||
| 1 | F | 73 | Secondary giant cell glioblastoma, Grade IV, IDH-mutant, Ki-67 – 22%, CD117+ cells – 8.8% | Left frontal and temporal lobes, at a depth of 5mm, 35x35x34mm | - | H, IHC, MA |
| 2 | F | 48 | small cell glioblastoma, Grade IV, IDH-wildtype, Ki-67 – 30%, CD117+ cells – 36.0% | Right frontal and parietal lobes, 55x42x39mm | - | H, IHC, MA |
| 3 | F | 59 | Giant cell glioblastoma with primitive neuronal component, Grade IV, IDH-wildtype, Ki-67 – 21%, CD117+ cells – 1.0% | Left parietal lobe, 17x13x17mm | - | H, IHC, MA |
| 4 | F | 60 | glioblastomas with primitive neuronal component, Grade IV, IDH-wildtype, Ki-67 – 50%, CD117+ cells – 1.1% | Left temporal lobe, 64x40x56mm | - | H, IHC, MA, CLSM |
| 5 | F | 64 | glioblastomas with primitive neuronal component, Grade IV, IDH-wildtype, Ki-67 – 32%, CD117+ cells – 2.5% | Right temporal lobe, 33x32x30mm | - | H, IHC, MA, CLSM |
| 6 | F | 73 | small cell glioblastoma, Grade IV, IDH-wildtype, Ki-67 – 30%, CD117+ cells – 5.2% | Right temporal lobe, at a depth of 1cm,36x35x44mm | - | H, IHC, MA, DSIHC, CLSM |
| 7 | F | 61 | small cell glioblastoma, Grade IV, IDH-wildtype, Ki-67 – 22%, CD117+ cells – 3.0% | Right parietal and occipital lobes, thalamus and basal nuclei, 36x36x39mm | - | H, IHC, MA, DSIHC, CLSM |
| 8 | F | 63 | small cell glioblastoma, Grade IV, IDH-wildtype, Ki-67 – 21%, CD117+ cells – 2.5%, CD117+ cells – 10.0% | Right frontal and parietal lobes, 37x30x29mm | - | H, IHC, MA, DSIHC |
| 9 | F | 61 | small cell glioblastoma, Grade IV, IDH-wildtype, Ki-67 – 28%, CD117+ cells – 56.0% | Right frontal lobe, thalamus, 45x72x54mm | - | H, IHC, MA, DSIHC |
| 10 | F | 61 | small cell glioblastoma, Grade IV, IDH-wildtype, Ki-67 – 22%, CD117+ cells – 12.0% | Right frontal and temporal lobes, 31x17x34mm | - | H, IHC, MA, DSIHC |
| 11 | F | 54 | small cell glioblastoma, Grade IV, IDH-wildtype, Ki-67 – 22%, CD117+ cells – 13.6% | Right frontal and temporal lobes, 47x28x20mm | - | H, IHC, DSIHC, MA |
| 12 | F | 60 | small cell glioblastoma, Grade IV, IDH-wildtype, Ki-67 – 28%, CD117+ cells – 3.0% | Left frontal and parietal lobes, 40x31x34mm | - | H, IHC, PC, CLSM, EM, MA |
| 13 | M | 62 | small cell glioblastoma, Grade IV, IDH-wildtype, Ki-67 – 22%, CD117+ cells – 8.8% | Right parietal lobe, 26x15x19mm | - | H, IHC, PC, CLSM, EM, MA |
| 14 | M | 56 | small cell glioblastoma, Grade IV, IDH-wildtype, Ki-67 – 31%, CD117+ cells – 36.0% | Right frontal and parietal lobes, 63x54x50mm | - | H, IHC, EM, MA |
| 15 | F | 76 | small cell glioblastoma, Grade IV, IDH-wildtype, Ki-67 – 22%, CD117+ cells – 10.0% | Right and left frontal lobes and corpus callosum, 65x54x52mm | - | H, IHC, EM, MA |
| Astrocytomas | ||||||
| 16 | F | 71 | diffuse astrocytomas, Grade II, NOS categories, Ki-67 – 2%, CD117+ cells – 1% | Left temporal lobe, 45x20x10mm | - | H, IHC, MA, DSIHC, PC, CLSM |
| 17 | M | 47 | diffuse astrocytomas, Grade II, NOS categories, Ki-67 – 4%, CD117+ cells – 2.5% | Right frontal and parietal lobes, 44x26x24mm | - | H, IHC, MA, DSIHC, PC, CLSM |
| 18 | M | 57 | diffuse astrocytomas, Grade II, NOS categories, Ki-67 – 4%, CD117+ cells – 1.6% | Left parietal and occipital lobes, corpus callosum, 84x66x11mm | - | H, IHC, MA |
| 19 | F | 40 | diffuse astrocytomas, Grade II, NOS categories, Ki-67 – 4% CD117+ cells – 0.7% | Right parietal lobe, thalamus, 33x30x30mm | - | H, IHC, MA |
| 20 | F | 61 | diffuse astrocytomas, Grade II, NOS categories, Ki-67 – 1,4%, CD117+ cells – 2.3% | Left frontal and parietal lobes, corpus callosum, 60x60x60mm | - | H, IHC, MA |
| 21 | M | 59 | diffuse astrocytomas, Grade II, NOS categories, Ki-67 – 2.5%, CD117+ cells – 1.3% | Left temporal lobe, 33x33x32mm | - | H, IHC, MA |
| 22 | M | 71 | diffuse astrocytomas, Grade II, NOS categories, Ki-67 – 4%, CD117+ cells – 1.2% | Right frontal lobe, 60x55x61mm | - | H, IHC, MA |
| 23 | F | 35 | diffuse astrocytomas, Grade II, NOS categories, Ki-67 – 3.6%, CD117+ cells – 1.0% | Right parietal lobe, 21x22x21mm | - | H, IHC, MA |
| 24 | F | 39 | diffuse astrocytomas, Grade II, NOS categories, Ki-67 – 2.9%, CD117+ cells – 2.0% | Left temporal lobe, 18x32x18 mm | - | H, IHC, MA |
| 25 | F | 60 | diffuse astrocytomas, Grade II, NOS categories, Ki-67 – 3.2%, CD117+ cells – 1.0% | Left temporal lobe, 10×11×12 mm | - | H, IHC, MA |
| Normal brain | ||||||
| 26 | M | 68 | Coronary artery disease, CD117+ cells –0.01% | no tumor | Pulmonary embolism | H, IHC, MA |
| 27 | M | 40 | Coronary artery disease, CD117+cells –0.17% | no tumor | Heart failure | H, IHC, MA |
| 28 | M | 53 | Coronary artery disease, CD117+ cells –0.38% | no tumor | Pulmonary embolism | H, IHC, MA |
| 29 | F | 51 | Coronary artery disease, CD117+ cells –0.23% | no tumor | Myocardial infarction | H, IHC, MA |
| 30 | F | 61 | Coronary artery disease, CD117+ cells- 0.5% | no tumor | Myocardial infarction | H, IHC, MA |
*2016 World Health Organization Classification of Tumors of the Central Nervous System [57]. Abbreviations: H, histology; PC, primary culture of telocytes from gliomas; IHC, immunohistochemistry; MA, morphometric analysis; DSIHC, double stain immunohistochemistry; CLSM, confocal laser scanning microscopy; EM, electron microscopy; MRI, magnetic resonance imaging; NOS categories, not otherwise specified (tumor samples were not tested for IDH gene mutations).